Figure 4From: Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in ratsPCSK9 levels during the treatment with Xuezhikang plus ezetimibe and pitavastatin plus ezetimibe. Δp < 0.05 versus Xuezhikang plus ezetimibe group. XZK: Xuezhikang.Back to article page